Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Hoes LR"" wg kryterium: Autor


Wyświetlanie 1-8 z 8
Tytuł :
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
Autorzy :
van der Wijngaart H; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Hoes LR; Oncode Institute, Utrecht, the Netherlands.; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
van Berge Henegouwen JM; Oncode Institute, Utrecht, the Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Rapenburg, Leiden, the Netherlands.
van der Velden DL; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Zeverijn LJ; Oncode Institute, Utrecht, the Netherlands.; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands.
van Werkhoven E; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Robbrecht DGJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Labots M; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
de Groot DJA; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands.
Hoeben A; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, the Netherlands.
Hamberg P; Department of Internal Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands.
Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Rapenburg, Leiden, the Netherlands.
Voest EE; Oncode Institute, Utrecht, the Netherlands.; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands. .
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Sep 02. Date of Electronic Publication: 2021 Sep 02.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Limited evolution of the actionable metastatic cancer genome under therapeutic pressure.
Autorzy :
van de Haar J; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands.
Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands.
Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands.
Lolkema MP; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
de Langen AJ; Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Smit EF; Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Cuppen E; Oncode Institute, Amsterdam, the Netherlands.; Hartwig Medical Foundation, Amsterdam, the Netherlands.; Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
Wessels LFA; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands.; Faculty of EEMCS, Delft University of Technology, Delft, the Netherlands.
Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. .; Oncode Institute, Amsterdam, the Netherlands. .; Center for Personalized Cancer Treatment, Rotterdam, the Netherlands. .
Pokaż więcej
Źródło :
Nature medicine [Nat Med] 2021 Sep; Vol. 27 (9), pp. 1553-1563. Date of Electronic Publication: 2021 Aug 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Evolution, Molecular*
Biomarkers, Tumor/*genetics
Neoplasm Proteins/*genetics
Neoplasms/*genetics
Adult ; Biopsy ; Female ; Genome, Human/genetics ; Genomics ; Humans ; Male ; Middle Aged ; Mutation/genetics ; Neoplasm Metastasis ; Neoplasms/classification ; Neoplasms/drug therapy ; Neoplasms/pathology ; Precision Medicine ; Small Molecule Libraries ; Whole Genome Sequencing/methods
Czasopismo naukowe
Tytuł :
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.
Autorzy :
Ooft SN; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Weeber F; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Schipper L; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Dijkstra KK; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
McLean CM; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Kaing S; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
van de Haar J; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Prevoo W; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Snaebjornsson P; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Hoes LR; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Chalabi M; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van der Velden D; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center AMC, Amsterdam, The Netherlands.
van Leerdam M; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Boot H; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Grootscholten C; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands.
Bloemendal HJ; Department of Internal Medicine/Oncology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.
Cuppen E; Oncode Institute, Utrecht, The Netherlands; Division of Biomedical Genetics, Centre for Molecular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Jun; Vol. 6 (3), pp. 100103. Date of Electronic Publication: 2021 Apr 19.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
Autorzy :
Samsom KG; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Bosch LJW; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Schipper LJ; Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands.
de Bruijn E; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Hoes LR; Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Riethorst I; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Schoenmaker L; Hartwig Medical Foundation, Amsterdam, The Netherlands.
van der Kolk LE; Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Retèl VP
Frederix GWJ
Buffart TE; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
van der Hoeven JJM; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Voest EE; Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, The Netherlands.
Cuppen E; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, The Netherlands.
Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. .
Meijer GA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
BMC medical genomics [BMC Med Genomics] 2020 Nov 10; Vol. 13 (1), pp. 169. Date of Electronic Publication: 2020 Nov 10.
Typ publikacji :
Clinical Trial Protocol; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Study
MeSH Terms :
Molecular Diagnostic Techniques*/economics
Molecular Diagnostic Techniques*/methods
Whole Genome Sequencing*/economics
Whole Genome Sequencing*/methods
Neoplasms/*diagnosis
Precision Medicine/*methods
Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Clinical Decision-Making ; DNA, Neoplasm/genetics ; Feasibility Studies ; Humans ; Neoplasms/chemistry ; Neoplasms/genetics ; Observational Studies as Topic ; Patient Selection ; Research Design ; Specimen Handling/methods ; Standard of Care ; Technology Assessment, Biomedical ; Workflow
Czasopismo naukowe
Tytuł :
Author Correction: Caring for patients with cancer in the COVID-19 era.
Autorzy :
van de Haar J; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Hoes LR; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Coles CE; Cancer Research UK Cambridge Cancer Center, Cambridge, UK.
Seamon K; Cancer Research UK Cambridge Cancer Center, Cambridge, UK.
Fröhling S; German Cancer Consortium, Heidelberg, Germany.; Division of Translational Medical Oncology, National Center for Tumor Diseases Heidelberg and German Cancer Research Center, Heidelberg, Germany.
Jäger D; Department of Medical Oncology, National Center for Tumor Diseases Heidelberg and Heidelberg University Hospital, Heidelberg, Germany.
Valenza F; Università Statale di Milano, Milan, Italy.; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
de Braud F; Università Statale di Milano, Milan, Italy.; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
De Petris L; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.; Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
Bergh J; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.; Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
Ernberg I; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Besse B; Gustave Roussy Cancer Campus, Villejuif, France.
Barlesi F; Gustave Roussy Cancer Campus, Villejuif, France.; Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.
Garralda E; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Piris-Giménez A; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Baumann M; German Cancer Consortium, Heidelberg, Germany.; German Cancer Research Center, Heidelberg, Germany.
Apolone G; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Soria JC; Gustave Roussy Cancer Campus, Villejuif, France.
Tabernero J; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Caldas C; Cancer Research UK Cambridge Cancer Center, Cambridge, UK. .; Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Center, University of Cambridge, Cambridge, UK. .
Voest EE; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. .; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. .
Pokaż więcej
Źródło :
Nature medicine [Nat Med] 2020 Jul; Vol. 26 (7), pp. 1146.
Typ publikacji :
Journal Article; Published Erratum
Czasopismo naukowe
Tytuł :
Caring for patients with cancer in the COVID-19 era.
Autorzy :
van de Haar J; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Hoes LR; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Coles CE; Cancer Research UK Cambridge Cancer Center, Cambridge, UK.
Seamon K; Cancer Research UK Cambridge Cancer Center, Cambridge, UK.
Fröhling S; German Cancer Consortium, Heidelberg, Germany.; Division of Translational Medical Oncology, National Center for Tumor Diseases Heidelberg and German Cancer Research Center, Heidelberg, Germany.
Jäger D; Department of Medical Oncology, National Center for Tumor Diseases Heidelberg and Heidelberg University Hospital, Heidelberg, Germany.
Valenza F; Università Statale di Milano, Milan, Italy.; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
de Braud F; Università Statale di Milano, Milan, Italy.; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
De Petris L; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.; Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
Bergh J; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.; Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
Ernberg I; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Besse B; Gustave Roussy Cancer Campus, Villejuif, France.
Barlesi F; Gustave Roussy Cancer Campus, Villejuif, France.; Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.
Garralda E; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Piris-Giménez A; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Baumann M; German Cancer Consortium, Heidelberg, Germany.; German Cancer Research Center, Heidelberg, Germany.
Apolone G; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Soria JC; Gustave Roussy Cancer Campus, Villejuif, France.
Tabernero J; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Caldas C; Cancer Research UK Cambridge Cancer Center, Cambridge, UK. .; Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Center, University of Cambridge, Cambridge, UK. .
Voest EE; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. .; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. .
Pokaż więcej
Źródło :
Nature medicine [Nat Med] 2020 May; Vol. 26 (5), pp. 665-671. Date of Electronic Publication: 2020 Apr 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Betacoronavirus*
Neoplasms*/complications
Neoplasms*/therapy
Coronavirus Infections/*epidemiology
Pneumonia, Viral/*epidemiology
Ambulatory Care/statistics & numerical data ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/prevention & control ; Delivery of Health Care ; Humans ; Pandemics/prevention & control ; Pneumonia, Viral/complications ; Pneumonia, Viral/prevention & control ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
Autorzy :
van der Velden DL; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.
Hoes LR; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.
van der Wijngaart H; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
van Berge Henegouwen JM; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
van Werkhoven E; Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Schilsky RL; American Society of Clinical Oncology, Alexandria, VA, USA.
de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Huitema ADR; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Nuijen B; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Nederlof PM; Department of Pathology, Molecular Diagnostics Laboratory, Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
de Groot DJA; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.
Devriese LA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Hoeben A; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands.
de Jonge MJA; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Chalabi M; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Smit EF; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
de Langen AJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Labots M; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Sleijfer S; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Cuppen E; Oncode Institute, Utrecht, The Netherlands.; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Verheul HMW; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Voest EE; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. .; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands. .; Oncode Institute, Utrecht, The Netherlands. .
Pokaż więcej
Źródło :
Nature [Nature] 2019 Oct; Vol. 574 (7776), pp. 127-131. Date of Electronic Publication: 2019 Sep 30.
Typ publikacji :
Controlled Clinical Trial; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Drug Discovery/*methods
Drug Repositioning/*trends
Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Female ; Humans ; Immunotherapy ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neoplasms/genetics ; Nivolumab/therapeutic use ; Precision Medicine ; Progression-Free Survival ; Research Design ; Young Adult
Czasopismo naukowe
Tytuł :
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.
Autorzy :
van Waalwijk van Doorn-Khosrovani SB; CZ Health Insurance, Tilburg.
Pisters-van Roy A; CZ Health Insurance, Tilburg.
van Saase L; National Health Care Institute (Zorginstituut Nederland), Diemen.
van der Graaff M; National Health Care Institute (Zorginstituut Nederland), Diemen.
Gijzen J; CZ Health Insurance, Tilburg.
Sleijfer S; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Center for Personalised Cancer Treatment (CPCT).
Hoes LR; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam.
van Berge Henegouwen JM; Division of Medical Oncology, Leiden University Medical Center, Leiden.
van der Wijngaart H; Division of Medical Oncology, Amsterdam University Medical Center, Cancer Center Amsterdam, Amsterdam.
van der Velden DL; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam.
van Werkhoven E; Department of Biometrics, Netherlands Cancer Institute, Amsterdam.
Retel VP; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam; Department of Health Technology and Services Research, University of Twente, Enschede.
van Harten WH; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam; Department of Health Technology and Services Research, University of Twente, Enschede; Rijnstate Hospital, Arnhem.
Huitema ADR; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam; Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
Timmers L; National Health Care Institute (Zorginstituut Nederland), Diemen.
Gelderblom H; Division of Medical Oncology, Leiden University Medical Center, Leiden.
Verheul HMW; Division of Medical Oncology, Leiden University Medical Center, Leiden.
Voest EE; Center for Personalised Cancer Treatment (CPCT); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 May 01; Vol. 30 (5), pp. 663-665.
Typ publikacji :
Editorial; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*genetics
Neoplasms/*drug therapy
Neoplasms/*economics
Precision Medicine/*economics
Reimbursement Mechanisms/*economics
Biomarkers, Tumor/metabolism ; Cost-Benefit Analysis ; Health Services Accessibility/economics ; Humans ; Molecular Diagnostic Techniques/economics ; Molecular Targeted Therapy/economics ; Neoplasms/classification ; Neoplasms/genetics ; Netherlands ; Survival Rate
Raport
    Wyświetlanie 1-8 z 8

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies